Claims
- 1. A compound of formula (I) ##STR526## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is
- a) --(C.sub.1 -C.sub.12 alkyl)--X, a
- b) --(C.sub.1 -C.sub.12 alkenyl)--X, or ##STR527## x is a) halogen,
- b) --CN,
- c) --NO.sub.2,
- d) --CF.sub.3,
- e) --NH.sub.2,
- f) --NHOR.sup.2,
- g) --NHC(.dbd.NH)R.sup.2,
- h) --NHC(.dbd.NH)NHOH,
- i) --NHC(.dbd.NH)NHNH.sub.2,
- j) --NHC(.dbd.NH)NHCN,
- k) --NHC(.dbd.NH)NHR.sup.2,
- l) --NHC(.dbd.NH)NHCOR.sup.2,
- m) --C(.dbd.NH)NHR.sup.2,
- n) --C(.dbd.NH)NHCOR.sup.2,
- o) --C(.dbd.O)NHR.sup.2,
- p) --CO.sub.2 R.sup.2,
- q) --OR.sup.2,
- r) --OCF.sub.3,
- s) --S(O).sub.r R.sup.2,
- t) --SC(.dbd.NH)NHR.sup.2, or
- u) --SC(.dbd.NH)NHC(.dbd.O)R.sup.2 ;
- R.sup.2 is
- a) hydrogen, or
- b) C.sub.1 -C.sub.4 alkyl;
- R.sup.3 is
- a) --C(.dbd.O)--(CH.sub.2).sub.p --CR.sup.6 R.sup.7 --(CH.sub.2).sub.q -aryl,
- b) --C(.dbd.O)--W--CR.sup.8 R.sup.9 -aryl, with the proviso that W cannot be a bivalent oxygen atom,
- c) --C(.dbd.O)--CR.sup.8 R.sup.9 --W--(CH.sub.2).sub.r -aryl, with the proviso that W cannot be --NR.sup.4 -- or --NC(.dbd.O)R.sup.4 --,
- d) --C(.dbd.O)--W--CR.sup.8 R.sup.9 -heteroaryl,
- e) --C(.dbd.O)--CR.sup.8 R.sup.9 --W--(CH.sub.2).sub.r -heteroaryl, with the proviso that W cannot be --NR.sup.4 -- or --NC(.dbd.O)R.sup.4 --,
- f) --C(.dbd.O)--W--CR.sup.8 R.sup.9 -heterocycle,
- g) --C(.dbd.O)--CR.sup.8 R.sup.9 --W--(CH.sub.2).sub.r -heterocycle, with the proviso that W cannot be --NR.sup.4 -- or --NCOR.sup.4 --,
- h) --C(.dbd.O)--(CH.sub.2).sub.t --W--(C.sub.5 -C.sub.7 cycloalkyl), ##STR528## wherein aryl is limited to phenyl, ##STR529## wherein aryl is limited to phenyl, ##STR530## with the proviso that R.sup.13 cannot be --N(C.sub.1 -C.sub.4 alkyl).sub.2 when A is --C(.dbd.O)R.sup.14, ##STR531## wherein aryl is limited to phenyl,
- t) --C(.dbd.O)--(CR.sup.8 R.sup.9)--NHS(O).sub.r R.sup.8, ##STR532## R.sup.4 and R.sup.5 are independently selected at each occurrence from the group consisting of: a) hydrogen,
- b) C.sub.1 -C.sub.4 alkyl,
- c) --(C.sub.1 -C.sub.4 alkyl)-aryl, or
- d) C.sub.5 -C.sub.7 cycloalkyl;
- R.sup.8 and R.sup.9 are independently selected at each occurrence from the group consisting of:
- a) hydrogen,
- b) C.sub.1 -C.sub.4 alkyl,
- c) C.sub.1 -C.sub.4 alkoxy,
- d) aryl,
- e) --(C.sub.1 -C.sub.4 alkyl)-aryl,
- f) --(C.sub.1 -C.sub.4 alkyl)-heterocycle,
- g) --O-aryl,
- h) --(CH.sub.2).sub.p --CO.sub.2 R.sup.4,
- i) R.sup.8 and R.sup.9 can be taken together to form a (C.sub.2 -C.sub.7) alkyl;
- R.sup.10 is:
- phenyl, wherein phenyl is optionally substituted with one to three substituents selected from the group consisting of halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.7 -C.sub.15 alkylaryl, C.sub.7 -C.sub.15 alkoxyaryl, methylenedioxy, --NO.sub.2, --CF.sub.3, --SH, --S(O).sub.r --(C.sub.1 -C.sub.4 alkyl), CN, --OH, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHCOR.sup.4, --(CH.sub.2).sub.p --CO.sub.2 R.sup.4 ;
- R.sup.11 is:
- a) --OR.sup.4,
- b) --NR.sup.15 R.sup.16,
- c) --NC(.dbd.O)R.sup.15 R.sup.16,
- d) --NR.sup.15 C(.dbd.O)OR.sup.4,
- e) aryl,
- f) --(C.sub.1 -C.sub.4 alkyl)-aryl,
- g) heteroaryl,
- h) --(C.sub.1 -C.sub.4 alkyl)-heteroaryl,
- i) --(C.sub.1 -C.sub.4 alkyl)--CO.sub.2 R.sup.4,
- j) heterocycle,
- k) --(C.sub.1 -C.sub.4 alkyl)heterocycle, ##STR533## R.sup.3 and R.sup.11, when taken together to form a ring bonded to the nitrogen: ##STR534## R.sup.13 is independently selected at each occurrence from the group consisting of:
- a) hydrogen
- b) halogen,
- c) C.sub.1 -C.sub.4 alkyl,
- d) C.sub.1 -C.sub.4 alkoxy,
- e) methylenedioxy,
- f) --NO.sub.2,
- g) --CF.sub.3,
- h) --SH,
- i) --S(O).sub.r --(C.sub.1 -C.sub.4 alkyl),
- j) --CN,
- k) --OH,
- l) --NH.sub.2,
- m) --NH(C.sub.1 -C.sub.4 alkyl),
- n) --N(C.sub.1 -C.sub.4 alkyl).sub.2,
- o) --NHC(.dbd.O)R.sup.4, or
- p) --(CH.sub.2).sub.p --CO.sub.2 R.sup.4 ;
- R.sup.14 is:
- a) --CF.sub.3,
- b) --CHF.sub.2,
- c) --CH.sub.2 F,
- d) --CH.sub.2 Cl,
- e) --C(.dbd.O)OR.sup.4,
- f) --C(.dbd.O)NR.sup.15 R.sup.16,
- g) --C(.dbd.O)R.sup.4,
- h) --C(.dbd.O)COOR.sup.4,
- i) --C(.dbd.O)C(.dbd.O)NR.sup.15 R.sup.16,
- j) --C(.dbd.O)C(.dbd.O)R.sup.4,
- k) --CY.sup.3 Y.sup.4 COOR.sup.4,
- l) --CY.sup.3 Y.sup.4 C(.dbd.O)NR.sup.15 R.sup.16, or
- m) --CY.sup.3 Y.sup.4 C(.dbd.O)R.sup.4 ;
- R.sup.15 and R.sup.16 are independently selected at each occurrence from the group consisting of:
- a) hydrogen,
- b) C.sub.1 -C.sub.4 alkyl,
- c) --(C.sub.1 -C.sub.4 alkyl)-aryl,
- d) C.sub.5 -C.sub.7 cycloalkyl, or
- e) phenyl, unsubstituted or substituted by R.sup.13 ;
- R.sup.15 and R.sup.16 taken together to form a ring can also include: ##STR535## R.sup.17 is:
- a) hydrogen,
- b) C.sub.1 -C.sub.4 alkyl,
- c) aryl,
- d) --(C.sub.1 -C.sub.4 alkyl)-aryl, or
- e) C.sub.5 -C.sub.7 cycloalkyl;
- R.sup.18 is:
- a) hydrogen,
- b) --(C.sub.1 -C.sub.5) alkyl, or
- c) --(C.sub.1 -C.sub.5) haloalkyl,
- d) --(C.sub.1 -C.sub.5) alkoxy;
- R.sup.19 is:
- a) hydrogen,
- b) --(C.sub.1 -C.sub.5) alkyl,
- c) halo, or
- d) --(C.sub.1 -C.sub.5) haloalkyl,
- e) --NO.sub.2,
- f) --NR.sup.4 R.sup.5,
- g) --CN,
- h) --(C.sub.1 -C.sub.5) alkoxy;
- A is:
- --BY.sup.1 Y.sup.2 ;
- W is
- a) --O--,
- b) --S(O).sub.r --,
- c) --NR.sup.4 --, or
- d) --NC(.dbd.O)R.sup.4 --;
- Y.sup.1 and Y.sup.2 are
- a) --OH,
- b) --F,
- c) --NR.sup.4 R.sup.5,
- d) C.sub.1 -C.sub.8 alkoxy, or
- when taken together Y.sup.1 and Y.sup.2 form:
- e) a cyclic boron ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O,
- f) a cyclic boron amide where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O,
- g) a cyclic boron amide-ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O;
- Y.sup.3 and Y.sup.4 are
- a) --OH or
- b) --F;
- n is 0 or 1;
- p is 0 to 3;
- q is 0 to 4;
- r is 0 to 2;
- t is 1 to 3;
- v is 1 to 17;
- wherein aryl is defined as phenyl, fluorenyl, biphenyl and naphthyl, which may be unsubstituted or include optional substitution with one to three substituents;
- heteroaryl is 2-, or 3-, or 4-pyridyl; 2- or 3-furyl; 2- or 3-benzofuranyl; 2-, or 3-thiophenyl; 2- or 3-benzo[b]thiophenyl; 2-, or 3-, or 4-quinolinyl; 1-, or 3-, or 4-isoquinolinyl; 2- or 3-pyrrolyl; 1- or 2- or 3-indolyl; 2-, or 4-, or 5-oxazolyl; 2-benzoxazolyl; 2- or 4- or 5-imidazolyl; 1- or 2-benzimidazolyl; 2- or 4- or 5-thiazolyl; 2-benzothiazolyl; 3- or 4- or 5-isoxazolyl; 3- or 4- or 5-pyrazolyl; 3- or 4-or 5-isothiazolyl; 3- or 4-pyridazinyl; 2- or 4- or 5-pyrimidinyl; 2-pyrazinyl; 2-triazinyl; 3- or 4-cinnolinyl; 1-phthalazinyl; 2- or 4-quinazolinyl; or 2-quinoxalinyl ring; said ring(s) may be unsubstituted or include optional substitution with one to three substituents;
- heterocycle is tetrahydroisoquinoline, tetrahydroquinoline, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, morpholino; said ring(s) may be unsubstituted or include optional substitution with one to three substituents;
- the substituents that may be attached to the aryl, heteroaryl and heterocycle ring(s) may be independently selected at each occurrence from the group consisting of:
- halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, methylenedioxy, --NO.sub.2, --CF.sub.3, --SH, --S(O).sub.r --(C.sub.1 -C.sub.4 alkyl)--CN, --OH, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl) --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHC(.dbd.O)R.sup.4, --(CH.sub.2).sub.p --CO.sub.2 R.sup.4, phenyl which may be unsubstituted or substituted with R.sup.13.
- 2. A compound of claim 1 wherein
- heteroaryl is 2-, 3-, or 4-pyridyl; 2-, or 3-furyl; 2-, or 3-thiophenyl; 2-, 3-, or 4-quinolinyl; or 1-, 3-, or 4-isoquinolinyl which may be unsubstitued or include optional substitution with one to three substituents; and
- heterocycle is 1-, 3-, or 4-tetrahydroisoquinolinyl, 2- or 3-pyrrolidinyl, and 2-, 3- or 4-piperidinyl which may be unsubstituted or include optional substitution with one to three substituents.
- 3. A compound of claim 2 wherein
- R.sup.3 is
- a) --C(.dbd.O)--(CH.sub.2).sub.p --CR.sup.6 R.sup.7 --(CH.sub.2).sub.q -aryl, ##STR536## wherein aryl is limited to phenyl; ##STR537## wherein aryl is limited to phenyl; or ##STR538##
- 4. A compound of claim 3 wherein R.sup.3 is hydrocinnamoyl and R.sup.11 is ##STR539##
- 5. A compound of claim 4 wherein R.sup.4 and R.sup.5 are both H.
- 6. A compound of claim 1 selected from the group consisting of: Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn-C10H16 HCl
- Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn(CH.dbd.NH)-C10H16 HCl
- Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroOrn(CH.dbd.NH)--OH HCl
- Hydrocinnamoyl-[N-(Phenethyl)-Gly]-boroArg(CH3)-C10H16 HCl
- Hydrocinnamoyl-[N-(N(CH3).sub.2)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(N(CH3).sub.2)-Gly]-boroLys--OH HCl
- Hydrocinnamoyl-[N-(N(CH3).sub.2)-Gly]-boroOrn-C10H16 HCl
- Hydrocinnamoyl-[N-(N(CH3).sub.2)-Gly]-boroOrn(CH.dbd.NH)-C10H16 HCl
- Methanesulfonyl-Gly-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(3-(Trifluoromethyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(3-(Trifluoromethyl)-Phenethyl)-Gly]-boroLys--OH HCl
- Hydrocinnamoyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys--OH HCl
- Succinyl-[N-(3-(Methyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(2,2-(Dimethyl)-Phenethyl)-Gly]-boroLys--OH HCl
- Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl
- Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroLys--OH HCl
- Hydrocinnamoyl-[N-(2-(Cyclopropyl)-Phenethyl)-Gly]-boroOrn(CH.dbd.NH)--OH HCl
- Hydrocinnamoyl-[N-(2,2-(Diethyl)-Phenethyl)-Gly]-boroLys-C10H16 HCl
- Acetyl-Gly[N-(2-(Benzyl)-Benzyl)]-boroLys-C10H16 HCl
- Pinanediol N-{N-methyl-N-[2-(pyrrol-1-ylmethyl)-Benzyl]glycyl}-1-amido-5-aminopentaneboronate, hydrochloride salt
- Phenoxyacetyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl
- Thiophenacetyl-[N-(Cyclopropyl)-Gly]-boroLys-C10H16 HCl
- Phenoxyacetyl-[N-(Cyclopropyl)-Gly]-boroLys--OH HCl
- Thiophenacetyl-[N-(Cyclopropyl)-Gly]-boroLys--OH HCl
- Glutaryl-[N-(Phenethyl)-Gly]-boroLys--OH HCl
- Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-C10H16
- Methyl Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl
- Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys--OH
- Methyl Glutaryl(3,3-Dimethyl)-[N-(Phenethyl)-Gly]-boroLys--OH HCl
- Boc-Asp-[N-(Phenethyl)-Gly]-boroLys-C10H16
- Boc-Glu-[N-(Phenethyl)-Gly]-boroLys-C10H16
- Boc-Glu(OCH3)-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl
- Boc-Glu-[N-(Phenethyl-Gly]-boroLys--OH
- Methanesylfonyl-Gly-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys-C10H16 HCl
- Methanesulfonyl-Gly-[N-(N-(Methyl)-Benzyl)-Gly]-boroLys--OH HCl
- Succinyl-[N-(Phenethyl)-Gly]-boroLys--OH
- Methyl Succinyl-[N-(Phenethyl)-Gly]-boroLys--OH HCl
- Glutaryl-[N-(Phenethyl)-Gly]-boroLys-C10H16
- Methyl Glutaryl-[N-(Phenethyl)-Gly]-boroLys-C10H16 HCl
- Methyl Glutaryl-[N-(Phenethyl)-Gly]-boroLys--OH HCl.
- 7. A pharmaceutical composition comprising a pharmaceutically suitable carrier and a therapeutically effective amount of a compound of claim 1.
- 8. A pharmaceutical composition comprising a pharmaceutically suitable carrier and a therapeutically effective amount of a compound of claim 2.
- 9. A pharmaceutical composition comprising a pharmaceutically suitable carrier and a therapeutically effective amount of a compound of claim 6.
- 10. A method of treating a physiological disorder in a warm blooded animal catalyzed by trypsin-like enzymes comprising administering to an animal in need such treatment an effective amount of a compound of claim 1.
- 11. A method of treating a physiological disorder in a warm blooded animal catalyzed by trypsin-like enzymes comprising administering to an animal in need such treatment an effective amount of a compound of claim 2.
- 12. A method of treating a physiological disorder in a warm blooded animal catalyzed by trypsin-like enzymes comprising administering to an animal in need such treatment an effective amount of a compound of claim 6.
CROSS-REFERENCE TO EARLIER FILED APPLICATIONS
This application is a division of U.S. patent application Ser. No. 08/642,817 filed May 3, 1996, now abandoned, which is a continuation of U.S. patent application Ser. No. 08/318,028 filed Oct. 4, 1994, now abandoned, which is continuation-in-part of U.S. patent application Ser. No. 08/139,445 filed Oct. 20, 1993 now abandoned.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4499082 |
Shenvi et al. |
Feb 1985 |
|
5169841 |
Kleeman et al. |
Dec 1992 |
|
5187157 |
Kettner et al. |
Feb 1993 |
|
5252566 |
Shuman |
Oct 1993 |
|
Foreign Referenced Citations (9)
Number |
Date |
Country |
B5288186 |
Jul 1986 |
AUX |
195212A2 |
Sep 1986 |
EPX |
363284A2 |
Apr 1990 |
EPX |
364344A2 |
Apr 1990 |
EPX |
0369391A2 |
May 1990 |
EPX |
417721A2 |
Mar 1991 |
EPX |
471651A2 |
Feb 1992 |
EPX |
WO 07869 |
May 1992 |
WOX |
WO 9212140 |
Jul 1992 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Gesellchen and Shuman J. Med. Chem 36, 314-319 (1993). |
Balasubramanian, et al. (J. Med. Chem 36, 300, (1993)). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
642817 |
May 1996 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
318028 |
Oct 1994 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
139445 |
Oct 1993 |
|